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Abstract
 
Multiple sclerosis (MS) is believed to be an autoimmune disease in which autoreactive T cells
infiltrate the central nervous system (CNS). Animal models of MS have shown that CNS-spe-
cific T cells are present in the peripheral T cell repertoire of healthy mice and cause autoim-
mune disease only when they are activated by immunization. T cell entry into the CNS is
thought to require some form of peripheral activation because the blood–brain barrier prohibits
trafficking of this tissue by naive cells. We report here that naive T cells can traffic to the CNS
without prior activation. Comparable numbers of T cells are found in the CNS of both healthy
 
recombinase activating gene (Rag)
 
2
 
/
 
2
 
 T cell receptor (TCR) transgenic mice and nontrans-
genic mice even when the transgenic TCR is specific for a CNS antigen. Transgenic T cells
isolated from the CNS that are specific for non-CNS antigens are phenotypically naive and pro-
liferate robustly to antigenic stimulation in vitro. Strikingly, transgenic T cells isolated from the
CNS that are specific for myelin basic protein (MBP) are also primarily phenotypically naive but
are unresponsive to antigenic stimulation in vitro. Mononuclear cells from the CNS of MBP
TCR transgenic but not nontransgenic mice can suppress the response of peripheral MBP-spe-
cific T cells in vitro. These results indicate that naive MBP-specific T cells can traffic to the
CNS but do not trigger autoimmunity because they undergo tolerance induction in situ.
Key words: trafﬁcking • T cell • experimental allergic encephalomyelitis • multiple sclerosis • 
transgenic
 
Introduction
 
Activation of self-reactive T cells is one of the first steps in
the development of autoimmune disease. The pool of au-
toreactive T cells available for activation is limited to a large
extent by mechanisms of tolerance induction that eliminate
self-reactive T cells (1). Animal models of autoimmune dis-
ease, however, demonstrate that some self-reactive T cells
remain in the periphery. These T cells are described as “ig-
norant” because they do not cause autoimmune disease
when encountering self-antigen in vivo unless the self-anti-
gen is presented in an immunostimulatory context (2, 3).
Experimental allergic encephalomyelitis (EAE),
 
1
 
 an animal
model of multiple sclerosis (MS), illustrates this phenome-
non. EAE is induced by immunization with central ner-
vous system (CNS) antigens such as myelin basic protein
(MBP) in CFA (4). Recognition of MBP in this context
activates naive T cells circulating in the periphery, which
then enter the CNS and initiate destruction of myelin (5).
In the absence of experimental intervention, the MBP-spe-
cific T cells are not activated and do not induce EAE.
CNS immune privilege is believed to be one of the main
components in maintaining ignorance in MBP-specific T
cells. Immune privilege is maintained within the CNS by
the blood–brain barrier that limits CNS trafficking by leu-
kocytes (6–8). Previous studies have suggested that only ac-
tivated T cells are able to cross the blood–brain barrier and
perform immune surveillance of the CNS (7, 9, 10).
Our studies use TCR transgenic mice specific for
MBP1-11 (11, 12), the predominant epitope targeted in
EAE in B10.PL mice (13). MBP1-11–specific T cells in the
periphery of TCR transgenic mice are primarily naive and
 
proliferate readily to MBP in vitro
 
 
 
(11, 14). EAE can be in-
duced in these mice by administration of pertussis toxin or
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combinase activating gene; RT, room temperature. 
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can occur spontaneously in an environment with increased
microbial exposure (14). In the studies reported here, we
analyzed the ability of the MBP1-11–specific T cells to
traffic to the CNS in the absence of any exogenous stimu-
lation. Surprisingly, comparable numbers of T cells were
isolated from the CNS of both MBP-specific TCR trans-
genic mice and wild-type mice. In contrast to wild-type
mice, however, most of the MBP-specific T cells found in
the CNS of young mice exhibited a naive phenotype rather
than an activated or memory phenotype. Similar observa-
tions were made in TCR transgenic models specific for
nonself antigens. TCR transgenic models differ signifi-
cantly from wild-type mice in that TCR transgenic mice
have few activated/memory peripheral T cells. These re-
sults indicate that, in the absence of activated T cells in the
periphery, naive T cells can traffic to the CNS. Despite the
trafficking of naive MBP-specific T cells through the CNS,
the majority of MBP TCR transgenic mice do not develop
autoimmunity. We show that the lack of spontaneous EAE
is due in part to suppression of the responses of naive
MBP-specific T cells within the target organ. Furthermore,
CNS cells from MBP TCR transgenic mice are able to
suppress the response of nontolerant peripheral MBP-spe-
cific T cells in vitro. These data demonstrate that CNS au-
toimmune disease is regulated in part by the induction of
tolerance to CNS antigens in situ.
 
Materials and Methods
 
Mice.
 
MBP TCR1 transgenic mice (B10.PL-H2
 
u
 
-H2-T18
 
a
 
[73NS]/Sn-TgN [TCR
 
a
 
]/BlJg and B10.PL-H2
 
u
 
-H2-T18
 
a
 
[73NS]/Sn-TgN [TCR
 
b
 
]/C14Jg [11]) and MBP TCR2 trans-
genic mice (12) were backcrossed onto B10.PL (73 NS)/Sn for at
least 11 generations. B10.PL (73 NS)/Sn, C57Bl/6J, and lym-
phocytic choriomeningitis virus (LCMV) TCR transgenic mice
(B6, D2-TgN (TCR LCMV) 327Sdz [15]) were obtained from
The Jackson Laboratory. Ovalbumin (Ova) TCR transgenic mice
(C57BL/6-TgN [TCR Ova] 1100Mjb [16]) and E
 
a
 
52-68:I-A
 
b
 
(TEa) TCR transgenic mice (17) were provided by Dr. Michael
Bevan (University of Washington, Seattle, WA) and Dr. Alex-
ander Rudensky (University of Washington, Seattle, WA), re-
spectively. DO11.10 TCR transgenic mice were provided by Dr.
Anne O’Garra (DNAX Research Institute, Palo Alto, CA). Mice
were maintained in a specific pathogen-free facility. The Animal
Care Committee of the University of Washington approved all
procedures used in this report.
 
Antibodies.
 
The following monoclonal antibodies were used
for flow cytometry: PE-conjugated anti-TCR
 
b
 
 (clone H57-597),
hamster anti-IgG (clone Ha4/8), rat anti-IgG (clone R35-95),
anti-CD3 (clone 17A2), anti-V
 
b
 
8.1,8.2 (clone MR5-2), and
anti-V
 
a
 
2 (clone B20.1); FITC-conjugated anti-CD44 (clone
IM7), anti-IgG (clone R35-95), anti-CD3 (clone 500-A2), anti-
CD4 (clone GK1.5), anti-CD8 (clone 53-6.7), anti-TCR
 
b
 
(clone H57.597), and anti-CD45RB (clone 16A); biotin-conju-
gated anti-TCR
 
b
 
 (clone H57.597), anti-CD49d (clone R1-2),
anti-IgG (clone R35-95), anti-V
 
b
 
8 (clone MR 5-2), anti-
CD45R (clone RA3-6B2), anti-CD8 (clone 53-6.7), anti-V
 
a
 
2
(clone B20.1), anti-CD4 (clone RM 4-5), anti-CD45RB (clone
16A), and anti-CD62L (clone MEL-14); and purified anti-
CD16/CD32 (Fc
 
g
 
 III/II receptor, clone 2.4 G2). All monoclonal
 
antibodies were purchased from BD PharMingen except anti-
CD3, which was purchased from Caltag. Biotin-conjugated pri-
mary monoclonal antibodies were detected by streptavidin-con-
jugated Tricolor from Caltag.
 
Flow Cytometry.
 
Single-cell suspensions (10
 
6
 
) of splenocytes,
LN cells, or CNS cells (10
 
5
 
) were resuspended in 10 
 
m
 
l of whole
mouse serum and anti-CD16/CD32 (0.05 
 
m
 
g/ml) for 15 min at
room temperature (RT). Samples were then incubated for 30
min at RT in the dark with primary antibodies diluted in 50 
 
m
 
l of
FACS
 
®
 
 staining buffer (FSB [0.05% sodium azide and 5% FCS;
Atlanta Biologicals] in PBS). Cells were washed, resuspended in
50 
 
m
 
l of secondary antibody diluted in FSB, and incubated for 20
min at RT. Cells were washed and resuspended in either 300 
 
m
 
l
of FSB or fixed in FSB with 0.37% formaldehyde. Cells (at least 3 
 
3
 
10
 
5
 
 per sample) were analyzed with a FACScan™ flow cytometer
(Becton Dickinson). Fluorescence is plotted on a log scale.
 
Lymphocyte Isolation.
 
Mice were anesthetized with a mixture
of xylazine (7 mg/kg), ketamine (100 mg/kg), and pentobarbital
(50 mg/kg) diluted in saline and administered by intraperitoneal
injection. Deeply anesthetized mice were perfused with 50 ml of
heparinized PBS via the left ventricle of the heart. The spinal
cords were removed via insufflation and the brain was dissected.
Both tissues were minced, dissociated with a 5-ml syringe
plunger, and strained through wire mesh (Small Parts). After cen-
trifugation, cells were resuspended in 37% Percoll (Amersham
Pharmacia Biotech), centrifuged at 2,118 
 
g
 
 for 15 min, washed,
and counted. To prepare cells for proliferation experiments,
pooled CNS samples were washed twice with 37% Percoll, resus-
pended in 30% Percoll, and layered over 70% Percoll. Cells har-
vested from the gradient interface were washed and resuspended
in complete media (DMEM; GIBCO BRL) supplemented with
essential amino acids (Irving Scientific), 9.5% FCS, 1.9 mM 
 
l
 
-glu-
tamine, 0.95 mM sodium pyruvate, 43 
 
m
 
M 
 
b
 
-mercaptoethanol,
95 U/ml penicillin G, 95 
 
m
 
g/ml streptomycin sulfate, and 0.1
mM nonessential amino acids. The amount of contamination of
the CNS mononuclear cell preparation with peripheral cells was
assessed using proflavin staining. Proflavin is a nuclear dye that
crosses the endothelium of most blood vessels easily but does not
cross the blood–brain barrier (18, 19). In two separate staining
experiments in which proflavin hydrochloride (20 
 
m
 
g/ml) was
administered intravenously, 
 
.
 
80% of the CNS mononuclear cells
did not stain positively for proflavin (data not shown).
Splenocytes were purified over a lympholyte M gradient (Ce-
darlane) and RBCs were lysed before staining. LNs (cervical, in-
guinal, brachial, and axillary) were teased with tweezers and fil-
tered through wire mesh (Small Parts) to create a single-cell
suspension. In some experiments, cervical and inguinal LNs were
harvested separately.
 
T Cell Stimulation Assay.
 
Single-cell suspensions of LN or
CNS mononuclear cells were plated at 1.5 
 
3
 
 10
 
4
 
 V
 
a
 
2
 
1
 
 T cells/
well (MBP TCR1, TEa TCR) or 2 
 
3
 
 10
 
4
 
 TCR
 
1
 
 T cells/well
(MBP TCR2, D011.10, and nontransgenic) in 96-well plates in
complete media. APCs (10
 
6
 
/well) consisted of splenocytes from
the appropriate wild-type mouse depleted of TCR
 
1
 
 cells by pan-
ning with anti-Thy 1.2 (clone 30-H12; BD PharMingen)–coated
plates (20), or by magnetic bead depletion using biotinylated anti-
TCR and streptavidin-coated Dynabeads (Dynal). MBP TCR1
and MBP TCR2 T cells were stimulated in the presence or ab-
sence of 30 
 
m
 
M MBP Ac1-11 peptide (Research Genetics) and T
cell–depleted APCs. TEa T cells were stimulated in the presence
or absence of 5 
 
m
 
g/ml E
 
a
 
52–68 peptide (a gift from Dr. Alex-
ander Rudensky) and T cell–depleted APCs. D011.10 T cells
were stimulated in the presence or absence of 1 
 
m
 
M Ova 323– 
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339 peptide (a gift from Dr. Craig Beeson, University of Wash-
ington, Seattle, WA) and T cell–depleted APCs. 5-Bromo-2
 
9
 
-
deoxyuridine (BrdU; 25 
 
m
 
g/ml; Sigma-Aldrich) was added after
48 h of culture and cells were harvested 12–16 h later. Prolifera-
tion was assessed by staining the cultured cells with PE-labeled
anti-V
 
a
 
2 (for MBP TCR1 and TEa transgenic mice) or anti-
TCR monoclonal antibody (for MBP TCR2 and DO11.10
TCR transgenic mice), cell permeabilization, and staining with
FITC-labeled anti-BrdU monoclonal antibody (clone 3D4; BD
PharMingen) as described previously (21, 22). For assessment of
anergy in CNS T cells, stimulations were performed as described
above except in the presence or absence of 50 U IL-2/ml (23).
 
Statistics.
 
The Student’s 
 
t
 
 test was used for a comparison of
the means between sample groups. Error bars represent one SD.
 
Results
 
MBP-specific T Cells Are Present in the CNS of Healthy An-
imals.
 
The high incidence of spontaneous EAE in recom-
binase activating gene (Rag)
 
2
 
/
 
2
 
 MBP TCR transgenic
mice suggests that T cells may be activated by encountering
MBP epitopes in vivo. Activation of MBP-specific T cells
within the CNS is only possible if some naive T cells gain
access to this tissue. To investigate this possibility, we iso-
lated lymphocytes from the brain and spinal cord of clini-
cally healthy, 4–7-wk-old, well perfused, MBP TCR1
transgenic mice on the Rag
 
1
 
/
 
1
 
 background. Lymphocytes
from individual animals were analyzed to avoid mixing
cells from any mice that had preclinical spontaneous EAE
with cells from healthy mice. Surprisingly, the number of
T cells per gram of CNS tissue isolated from young,
healthy MBP TCR1 transgenic mice was comparable to
the number isolated from nontransgenic control mice (Fig.
1). This result was unexpected because entry into the CNS
is believed to be limited to activated T cells (7, 9, 10), and
TCR transgenic mice typically have few activated T cells
in the periphery (14, 24).
A second MBP TCR transgenic model (MBP TCR2)
also demonstrated normal numbers of T cells within the
CNS compared with age-matched nontransgenic mice
(Fig. 1). Of eight MBP TCR2 transgenic mice analyzed,
only one mouse exhibited an abnormally high number of T
cells (1.5 
 
3
 
 10
 
6
 
 T cells/g, 100-fold higher than the average
T cell count). Data from this mouse were not included in
Fig. 1 because of the possibility that this animal was devel-
oping spontaneous disease.
 
The number of T cells in the CNS of Rag
 
2
 
/
 
2
 
 MBP
TCR transgenic mice was also analyzed to determine if the
expression of endogenous TCRs influenced the ability of
transgenic T cells to enter the CNS. The number of T cells
isolated from the CNS of Rag
 
2
 
/
 
2
 
 MBP TCR transgenic
mice were comparable to the number isolated from non-
transgenic mice and Rag
 
1
 
/
 
1
 
 TCR transgenic mice (Fig. 1).
 
T Cells in the CNS of Young TCR Transgenic Mice Are Pre-
dominantly Naive.
 
Previous studies in nontransgenic mice
indicated that only activated T cells cross the blood–brain
barrier (7, 9, 10). To investigate whether the T cells found
in the CNS of TCR transgenic mice also display an acti-
vated phenotype, T cell populations in 4–7-wk-old non-
transgenic (controls) and Rag
 
2
 
/
 
2 
 
MBP TCR transgenic
mice were analyzed using antibodies specific for cell-sur-
face activation/memory markers. In nontransgenic mice,
the majority of CNS T cells expressed high levels of CD44
as well as low levels of CD45RB (Fig. 2) and high levels of
CD49d (data not shown), consistent with an activated/
memory phenotype. Peripheral T cells from nontransgenic
mice expressed significantly lower levels of these activa-
Figure 1. Similar numbers of
T cells are isolated from the
CNS of MBP TCR transgenic
mice and nontransgenic (Ntg)
mice on both the Rag2/2 and
Rag1/1 background. CNS lym-
phocytes were collected as de-
scribed in Materials and Methods
and stained with anti-TCR
monoclonal antibodies. Error
bars represent one SD.
Figure 2. T cells in the CNS of TCR transgenic mice have a predom-
inately naive phenotype. T cells were harvested from the CNS (solid
lines) and spleen (dotted lines) as described in Materials and Methods, and
stained with monoclonal antibodies specific for TCR, CD44, and
CD45RB. The indicated percentage of naive CNS T cells represents the
average percentage of TCR1 cells 6 one SD that are neither CD44hi nor
CD45RBlo (as indicated by the bars). 
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tion/memory markers compared with CNS T cells (
 
P
 
 
 
5
 
0.002). These observations are consistent with earlier stud-
ies showing that the CNS is preferentially trafficked by ac-
tivated T cells.
Our analysis also revealed that the ratio of CD8
 
1
 
/CD4
 
1
 
T cells is more than twofold higher in the CNS than in the
spleen in nontransgenic mice (data not shown). The basis for
this CD8
 
1
 
 enrichment in the CNS is not clear; however, it
may reflect the fact that a higher percentage of CD44
 
high
 
 T
cells are found in the CD8
 
1
 
 peripheral T cell subset com-
pared with the CD4
 
1
 
 peripheral T cell subset (28 
 
6
 
 3.5%
versus 19 
 
6
 
 3.9%, respectively,
 
 n 
 
5 
 
4) in wild-type mice.
The phenotype of T cells in both the periphery and
CNS of Rag
 
2
 
/
 
2
 
 MBP TCR transgenic mice was strikingly
different from the phenotype seen in nontransgenic mice.
The highly restricted TCR repertoire in Rag
 
2
 
/
 
2
 
 TCR
transgenic mice limits the ability of these T cells to be acti-
vated by environmental antigens. Therefore, the percent-
age of CD44
 
high
 
 splenocytes in both Rag
 
2
 
/
 
2
 
 MBP TCR1
and Rag
 
2
 
/
 
2
 
 MBP TCR2 transgenic mice was 10-fold
lower than the percentage in nontransgenic mice (Fig. 2).
Unexpectedly, the majority of T cells isolated from the
CNS of Rag
 
2
 
/
 
2 MBP TCR1 and MBP TCR2 transgenic
mice also exhibited a naive phenotype characterized by low
levels of CD44 (Fig. 2) and CD49d (data not shown), and
primarily intermediate to high levels of CD45RB (Fig. 2).
The data described above suggest that reducing the
number of activated T cells in the periphery does not di-
minish trafficking to the CNS, but instead allows more na-
ive T cells to gain entry. This hypothesis predicts that the
CNS of other Rag2/2 TCR transgenic mice should also
contain similar numbers of T cells as the CNS of wild-type
mice, and that the CNS T cells in the TCR transgenic
mice should display a naive phenotype. To test these pre-
dictions, CNS T cells were isolated from two other Rag2/2
TCR transgenic models that were not specific for CNS an-
tigens. In Rag2/2 LCMV and Rag2/2 Ova TCR trans-
genic mice, the number of T cells isolated per gram of
CNS tissue was again comparable to the number of T cells
isolated from nontransgenic control mice (data not shown).
T cells isolated from the CNS of both of these transgenic
models also express low levels of CD44 and CD49d, and
intermediate to high levels of CD45RB (Fig. 2 and data
not shown).
In each Rag2/2 TCR transgenic model except Rag2/2
MBP TCR1 transgenic mice, the percentage of naive T
cells (CD45RBhigh, CD44low) found in the CNS is .80%
compared with ,30% in nontransgenic mice (Fig. 2).
Rag2/2 MBP TCR1 transgenic mice are unique in that
they appear to contain a higher percentage of CD45RBlow
T cells in the CNS than the other transgenic models, and
consequently a lower percentage of naive T cells. Interest-
ingly, MBP TCR1 transgenic mice on a Rag1/1 back-
ground also differ significantly from MBP TCR2 trans-
genic mice in their incidence of spontaneous EAE. In a
conventional animal facility, the incidence of spontaneous
EAE is 45% in MBP TCR1 mice but only 11% in MBP
TCR2 transgenic mice (25).
In our analyses of T cell phenotype, we also examined
the expression of CD62L, an LN homing receptor typically
expressed on naive T cells (26, 27). In the periphery of
both nontransgenic and TCR transgenic mice, CD62L was
predominantly expressed on naive T cells (defined by ex-
pression of CD44, CD49d, or CD45RB) as expected. Sur-
prisingly, in nontransgenic and TCR transgenic models,
CD62L expression was observed on CNS T cells that ex-
hibited activation/memory markers as well as on naive T
cells, and did not correlate with either phenotype. CNS
lymphocytes were enriched for CD62Llow cells compared
with splenocytes in nontransgenic animals (CNS, 47 6 7%;
spleen, 10 6 7%; n 5 3), Rag2/2 MBP TCR2 transgenic
mice (CNS, 46 6 11%; spleen, 7 6 2%; n 5 3), Rag2/2
Ova transgenic mice (CNS, 64 6 10%; spleen, 10 6 1%; n 5
4), and Rag2/2 LCMV transgenic mice (CNS, 52 6 17%;
spleen, 9 6 4%; n 5 3). This general enrichment of
CD62Llow cells in the CNS and lack of correlation with ex-
pression of activation markers suggest that CD62L is not
strictly a naive T cell marker, and its downregulation in
some cases may occur independently of T cell activation.
MBP-specific T Cells Convert to Memory Cells with Age.
The observation that young Rag2/2 MBP TCR1 trans-
genic mice have a similar percentage of CD45RBlow T cells
in the CNS and spleen as nontransgenic mice suggested
that interactions with the MBP-specific TCR on these cells
promotes the accumulation of T cells with a memory phe-
notype. Antigenic stimulation could be provided by MBP
itself, by a cross-reactive self-antigen, or environmental an-
tigen. In wild-type mice, the percentage of memory T cells
increases with age in the peripheral lymphoid compart-
ments, presumably due to an increased number of encoun-
ters with environmental antigens (28). We hypothesized
that a similar increase in the number of memory T cells
should be observed in MBP TCR1 transgenic mice if T
cells in these animals are continuously interacting with an-
tigen. Analyzing T cell populations in the spleen and CNS
of MBP TCR1 transgenic mice and nontransgenic mice as
a function of age tested this prediction. Rag1/1 instead of
Rag2/2 MBP TCR1 transgenic mice were analyzed be-
cause older Rag2/2 MBP TCR transgenic mice exhibit a
100% incidence of spontaneous EAE (12). In contrast,
Rag1/1 MBP TCR1 transgenic mice exhibit EAE prima-
rily between 5 to 10 wk of age, but very few cases of EAE
are observed in mice .69 d of age (14). Older MBP
TCR1 transgenic mice (.69 d) exhibited a significant
increase in the percentage of activated/memory cells
(CD45RBlow, CD44high) in both the CNS and the periph-
ery compared with young MBP TCR1 transgenic mice (P 5
0.0006; Fig. 3 and Table I). Furthermore, the age-depen-
dent decrease in naive T cells was significantly greater in
MBP TCR1 transgenic mice than in nontransgenic mice
(P 5 0.0003). A similar age-dependent decrease in naive T
cells is seen in MBP TCR2 transgenic mice (data not
shown).
Several observations support the idea that the increase in
memory T cells in Rag1/1 MBP TCR transgenic mice re-
sults from interactions via the MBP-specific TCR rather875 Brabb et al.
than interactions with environmental antigens via endoge-
nously rearranged TCRs. First, the absolute number of
CNS T cells per gram of tissue in older MBP TCR trans-
genic mice is significantly greater than the number found in
older nontransgenic mice (1.4 3 104 CNS T cells in non-
transgenic mice, n 5 11; 6.0 3 104 CNS T cells in MBP
TCR1 mice, n 5 10, P 5 0.0007; 7.1 3 104 CNS T cells
in MBP TCR2 mice, n 5 3, P 5 0.007). This observation
suggests that expression of the MBP TCR results in more
antigenic stimulation than the diverse repertoire of TCRs
expressed in nontransgenic mice. Second, the absolute
number of both total MBP-specific (Va21) T cells and
CD45RBlow V a21 T cells increases with age within the
CNS in MBP TCR1 transgenic mice, suggesting that the
increase in memory T cells does not simply reflect an in-
crease in T cells with endogenously rearranged TCR
chains (data not shown, P 5 0.00004). These data are in
contrast to results from MHC class II–restricted TCR
transgenic mice specific for a nonself antigen, pigeon cyto-
chrome C (24). In this model, there was an increase in pe-
ripheral memory T cells as the animals aged; however, this
increase was completely in the transgene-negative T cells
rather than the transgene-positive T cells. Our data dem-
onstrate that as MBP TCR transgenic mice age, an increas-
ing number of T cells expressing MBP-specific TCRs are
activated and converted to a memory phenotype in the ab-
sence of spontaneous EAE.
Tolerance Is Induced in MBP-specific Naive T Cells That
Enter the CNS. The observation that activated/memory
MBP-specific T cells are found in higher numbers in the
Figure 3. The number of CNS T cells display-
ing a naive phenotype significantly decreases as
MBP TCR1 transgenic mice age. CNS (r) and
splenic (h) T cells were harvested from 21 non-
transgenic and 13 MBP TCR1 transgenic mice of
different ages and stained with anti-TCR, anti-
CD44, and anti-CD45RB monoclonal antibodies.
Percent naive represents the percentage of TCR1
cells that are neither CD44hi nor CD45RBlo, as
indicated in Fig. 2.
Table I. Activated/Memory Phenotypes of CNS and Splenic T Cells from Older (.10 wk) TCR Transgenic and Nontransgenic Mice
Percentage of
naive
Percentage of
CD49d high
Percentage of
CD44 high
Percentage of
CD45RB low
CNS Spleen CNS Spleen CNS Spleen CNS Spleen
B10.PL 17.7 6 7.9 51.7 6 4.9 37.7 12.2 57.9 6 11.1 26.8 6 7.4 63.9 6 5.8 32.9 6 2.8
NTG n = 9 n = 9 n = 1 n = 1 n = 10 n = 10 n = 11 n = 11
MBP 6.8* 6 3.8 24.4* 6 11.1 ND ND 69.3 6 15.2 31.7 6 9.3 79* 6 6.5 63.6* 6 11.4
TCR1 n = 9 n = 9 n = 9 n = 9 n = 10 n = 10
MBP 12.1 6 0.7 38.8* 6 0.1 ND ND 39.5* 6 7 17.2 611 78.8* 6 8.6 49.9* 6 2.4
TCR2 n = 2 n = 2 n = 5 n = 5 n = 2 n = 2
C57Bl/6 18.7 41.2 ND ND 62.7 36.4 65.3 34.4
Ntg n = 1 n = 1 n = 1 n = 1 n = 1 n = 1
Rag2/2 84.4 84.6 8.3 6 2.1 1 6 1 19.3 6 11.8 8.5 6 1.7 7.7 9.8
Ova n = 1 n = 1 n = 3 n = 3 n = 4 n = 4 n = 1 n = 1
*Refers to P , 0.01 when compared with the appropriate nontransgenic (Ntg) value.876 In Situ Tolerance within the CNS
CNS of healthy, older transgenic mice than in younger
mice was inconsistent with the fact that the incidence of
spontaneous EAE is significantly higher in younger rather
than older mice. Therefore, we investigated the possibility
that, in contrast to activated T cells, naive MBP-specific
transgenic T cells entering the CNS undergo tolerance in
situ and become unresponsive to MBP. CNS T cells iso-
lated from 14–17 healthy MBP TCR1 transgenic mice
were pooled and cultured in vitro with MBP Ac1-11. T
cell–depleted splenocytes from wild-type mice were added
as APCs. Va21 T cells isolated from the CNS of MBP
TCR1 transgenic mice did not proliferate in response to
antigen (Fig. 4, A and B, P 5 0.004). In contrast, Va21 T
cells from LNs of the same animals plated at the same den-
sity as the CNS T cells proliferated robustly in response to
MBP Ac1-11. CNS T cells isolated from MBP TCR2
transgenic mice also did not proliferate in response to anti-
gen, whereas LN T cells proliferated strongly (Fig. 4 B). To
determine whether the induction of nonresponsiveness in
T cells within the CNS was unique to T cells specific for
MBP, two different MHC class II–restricted TCR trans-
genic mouse models specific for non-CNS antigens were
analyzed using the same experimental protocol. Both CNS
and LN T cells harvested from TEa TCR transgenic mice
specific for the MHC class II Ea peptide and DO11.10
TCR transgenic mice specific for ovalbumin proliferated
equally when stimulated with Ea peptide and Ova peptide,
respectively, in vitro (Fig. 4 B). Thus, nonresponsiveness of
T cells from the CNS was observed only when the T cells
were specific for a CNS antigen.
Previous studies of tolerance to tissue-specific antigens
have implicated draining LNs as the site for induction of T
cell tolerance. Therefore, we investigated the possibility
that nonresponsiveness may be induced in the MBP-spe-
cific T cells by presentation of MBP epitopes in the cervical
LNs that are believed to drain the CNS (29, 30). In the ex-
periments in Fig. 4 B, T cells from multiple peripheral LNs
draining different tissues were pooled together such that
nonresponsiveness in the cervical LNs might not have been
detected. Fig. 4 C compares the proliferative responses to
MBP Ac1-11 of Va21 T cells isolated from the cervical and
inguinal LNs of MBP TCR1 transgenic mice. T cells from
both types of LNs proliferated strongly to MBP peptide,
supporting the idea that induction of tolerance in MBP-
specific T cells occurs within the CNS itself.
Mononuclear Cells within the CNS of MBP TCR Transgenic
Mice Actively Suppress the Response of MBP-specific T Cells
from the Periphery. To investigate the mechanism of toler-
ance induction in the CNS, we first determined if the
MBP-specific T cells isolated from the CNS were anergic.
CNS T cells from both MBP TCR1 and MBP TCR2
transgenic mice were harvested and stimulated with MBP
Ac1-11 and irradiated APCs in the presence and absence of
IL-2. CNS T cells isolated from both transgenic models re-
mained nonresponsive to antigen even in the presence of
IL-2, whereas LN T cells from the same mice proliferated
robustly (data not shown). Therefore, the lack of prolifera-
tion observed with MBP-specific T cells from the CNS
was not due to an ability to produce IL-2. In all experi-
ments described so far, no more than 21 MBP TCR trans-
genic mice were pooled per experiment. In one additional
experiment, 36 MBP TCR1 TCR transgenic mice were
pooled in order to expand the number of wells exposed to
IL-2. In this experiment, both CNS and LN T cells prolif-
erated in the presence and absence of IL-2 (data not
shown). No proliferation was detected in any of the other
experiments using MBP TCR transgenic CNS T cells (n 5
5). Therefore, we suspect that the unusually large number
of mice pooled in this experiment included a mouse with
subclinical EAE. The incidence of spontaneous EAE in the
colony from which these mice were obtained is 15%. T
cells in the CNS of mice with subclinical EAE will already
be activated and would be expected to proliferate in vitro.
We next investigated whether the mononuclear cells iso-
lated from the CNS of MBP TCR transgenic mice could
actively suppress the responses of T cells isolated from the
periphery of the same mice that have not undergone toler-
ance induction. In control experiments, LN T cells (2 3
104) from MBP TCR1 or TCR2 transgenic mice were
cultured with and without MBP peptide and either irradi-
Figure 4. CNS T cells from MBP TCR1 and MBP TCR2 transgenic
mice do not proliferate in response to antigen while MBP transgenic T
cells recovered from CNS-draining cervical LNs (CLN) or nondraining
inguinal LNs (ILN) proliferate well. (A) Flow cytometric analysis measur-
ing the proliferation of pooled CNS T cells purified from spinal cords of
17 MBP TCR1 transgenic mice and LN T cells from the same animals.
CNS and LN T cells were separately incubated with irradiated T cell–
depleted wild-type splenic APCs with and without MBP Ac 1-11. Prolifer-
ating T cells are identified as BrdU1 cells as indicated by the bar. (B)
Comparison of the proliferation of CNS and LN T cells from different
TCR transgenic models in response to antigenic stimulation. Experiments
were performed as described in panel A and the data represent an average
of three experiments using MBP TCR1 transgenic mice and one experi-
ment each pooling 15–17 MBP TCR2, DO11.10, and TEa TCR trans-
genic mice. For MBP TCR1 and TEa TCR transgenic mice, prolifera-
tion of Va21 CNS and LN T cells is shown. For MBP TCR2 and
DO11.10 TCR transgenic mice, proliferation of TCR1 rather than Va21
T cells is shown. (C) The percentage of proliferating (BrdU1) Va21 T
cells was determined for T cells harvested from the CLN and ILN (n 5
2). Mice used for all of these experiments were 4–12 wk of age.877 Brabb et al.
ated APCs alone or with irradiated APCs and CNS cells
isolated from 15 to 17 nontransgenic mice. The transgenic
LN T cells proliferated strongly to MBP Ac1-11 in both
the presence and absence of CNS mononuclear cells iso-
lated from nontransgenic mice (Fig. 5). These results con-
firm our observations made with the TEa and DO11.10
TCR transgenic mice that CNS mononuclear cells do not
generally suppress T cell proliferation. Interestingly, CNS
cells isolated from MBP TCR transgenic mice had a very
different effect in these experiments. Proliferation of MBP-
specific LN T cells was significantly inhibited upon incuba-
tion with CNS cells isolated from MBP TCR transgenic
mice compared with incubation with peptide and irradi-
ated APCs alone (Fig. 5, P 5 0.004). These data are the re-
sults of four independent experiments using CNS cells
from MBP TCR transgenic mice. Thus, mononuclear cells
present only in MBP TCR transgenic mice and not non-
transgenic mice are capable of mediating bystander suppres-
sion of nontolerant MBP-specific peripheral T cells.
Discussion
Our studies show that multiple mechanisms are responsi-
ble for maintaining the immunologically privileged status
of the CNS. Previous work indicated that immunological
privilege was the result of the specialized structure of the
blood–brain barrier that limited T cell trafficking to acti-
vated T cells (7, 9, 10). Our data support the notion that T
cells found in the CNS of wild-type mice are predomi-
nantly activated/memory T cells. However, recent experi-
ments in sheep demonstrated that naive lymphocytes in-
fused directly into the blood could circulate through the
cerebral spinal fluid (CSF [31]). Our experiments suggest a
basis for reconciling these apparently conflicting findings.
We show that the same number of T cells are found in the
CNS of nontransgenic, TCR transgenic, and even Rag2/2
TCR transgenic mice that have very few activated T cells
in the periphery. Thus, a similar number of T cells traffic
through the CNS of healthy animals regardless of the num-
ber of activated T cells present in the periphery. The CNS
of nontransgenic mice is enriched in activated/memory T
cells, suggesting that activated T cells have a competitive
advantage over naive T cells in crossing the blood–brain
barrier. However, as the number of activated T cells in the
periphery decreases, more naive T cells are able to enter
the CNS. This is most clearly illustrated in Rag2/2 TCR
transgenic mice in which there are very few activated T
cells in the periphery and the vast majority of T cells in the
CNS exhibit a naive phenotype.
The increased ability of activated/memory T cells to
cross the blood–brain barrier may explain our finding in
nontransgenic mice that more CD81 T cells are found
within the CNS than CD41 T cells. In the periphery of
nontransgenic mice, the activated/memory T cell popula-
tion contains a greater percentage of CD81 than CD41 T
cells. The CD44high T cell population in the periphery has
been shown to have a higher percentage of CD81 T cells
relative to CD41 T cells in other models as well (32). Al-
ternatively, experiments in a different system suggest that
CD81 T cells may preferentially traffic through the CNS
(33). In these studies, dendritic cells and moth–cytochrome
C peptide were injected into the CSF of MHC class II–
restricted moth–cytochrome C peptide TCR transgenic
mice. Preferential recruitment of MHC class I–restricted
cells to the CNS was observed even though MHC class II
molecules presented the stimulating antigen. These findings
and our results are both consistent with enhanced re-circu-
lation or accumulation of CD81 T cells through the CNS.
An important implication of our results is that circulation
of autoreactive naive T cells through the CNS represents a
potential trigger of autoimmune disease. Although the de-
gree of trafficking through the CNS by naive T cells is
greater in Rag2/2 TCR transgenic mice than in nontrans-
genic mice, some trafficking of the CNS by naive T cells
occurs continuously in nontransgenic animals. We demon-
strate that initiation of autoimmunity by these naive T cells
in the CNS is specifically prevented by the induction of
tolerance in situ. Naive MBP-specific T cells isolated from
the CNS are unresponsive to antigen while MBP-specific
T cells from the periphery of the same animals are fully
functional in response to antigen stimulation. Induction of
tolerance is unique to MBP-specific T cells present in the
CNS, as CNS T cells isolated from TCR transgenic mice
specific for non-CNS antigens are not tolerized and prolif-
erate robustly in response to antigen in vitro.
Previous studies of T cell tolerance to tissue-specific an-
tigens indicated that tolerance occurred in LNs draining the
relevant tissue. For example, T cells specific for antigens
expressed in the pancreas undergo deletion within the LNs
draining the pancreas (34–38). In contrast, we demonstrate
that induction of tolerance in MBP-specific T cells occurs
within the target organ itself rather than within a lymphoid
tissue. First, we confirmed that our CNS T cell isolation
procedures from MBP TCR transgenic mice produced T
cells that were present behind the blood–brain barrier in
vivo without significant contamination of peripheral T cells
(see Materials and Methods). Second, we examined T cells
isolated from cervical LNs for evidence of tolerance be-
cause these LNs are believed to drain the CNS (29, 30).
Figure 5. CNS mononuclear
cells harvested from MBP TCR
transgenic but not nontrans-
genic mice inhibit proliferation
of MBP-specific peripheral LN
cells in vitro. MBP TCR trans-
genic T cells isolated from pe-
ripheral LN cells were incubated
with MBP Ac1-11 and irradiated
APCs as described in the legend
to Fig. 4 without (black bars) and
with (hatched bars) additional
CNS mononuclear cells. CNS
mononuclear cells were isolated
from 15–17 MBP TCR transgenic or nontransgenic mice. These data
represent four experiments using CNS mononuclear cells from MBP
TCR2 transgenic mice and three experiments using CNS mononuclear
cells from nontransgenic mice. Mice used for these experiments were 4–12
wk of age. Tg, transgenic.878 In Situ Tolerance within the CNS
We found that T cells from these LNs proliferated as ro-
bustly as T cells from other LNs and significantly more
than T cells from the CNS. Thus, tolerance does not ap-
pear to occur in the draining LNs but rather occurs in the
CNS itself.
It is not yet clear whether in situ tolerance induction is
unique to the CNS and constitutes an aspect of immune
privilege of this organ, or whether tissue-specific tolerance
occurs in other organs as well. Exposure of naive T cells to
antigens within parenchymal tissues has been suggested as a
basis for some forms of neonatal tolerance. T cell trafficking
through extra-lymphoid tissues is thought to occur more
extensively in neonates than in adult mice. However, in at
least one example the tolerance induced in neonates by in-
creased trafficking of peripheral tissues was systemic toler-
ance and did not result in the presence of tolerant T cells
exclusively in the relevant tissue (39). In contrast to these
findings, we demonstrate that the tolerance to MBP within
the CNS is tissue-specific rather than systemic.
Our investigation of the mechanism of tolerance induc-
tion in naive MBP-specific T cells entering the CNS
showed that tolerance does not occur through downregu-
lation of TCR or CD4 because the expression of these re-
ceptors on CNS T cells is comparable to that observed on
peripheral T cells (data not shown). Inhibition of prolifera-
tion of CNS MBP-specific T cells is not mediated by in-
hibitory factors found in the CSF or brain during inflam-
mation that appear to modulate T cell activity (40, 41).
These factors operate within the microenvironment of the
inflamed CNS and would not be present in our in vitro
cultures. In addition, naive CD41 T cells specific for non-
CNS antigens proliferate equally well when they are iso-
lated from either the CNS or LNs, and it is only T cells
from MBP TCR transgenic mice that are nonresponsive.
Our data suggest instead that the interaction of naive MBP-
specific T cells with antigen in the CNS results in an irre-
versible state of nonresponsiveness that is maintained even
in the absence of soluble factors found in CNS microenvi-
ronments during inflammation. The nonresponsiveness in-
duced in MBP-specific T cells in situ was not reversed by
addition of exogenous IL-2 in vitro; however, in vivo in-
duction of T cell anergy is not necessarily overcome by ad-
dition of exogenous IL-2 (42–46). Influenza hemaggluti-
nin–specific TCR transgenic T cells that have been
anergized in vivo have been shown to contain high levels
of IL-4 and IL-10 mRNA, suggesting that the anergic T
cells may function as regulatory T cells (46). This phenom-
enon could explain our finding that mononuclear cells iso-
lated from the CNS of MBP TCR transgenic mice are
capable of suppressing the proliferation of nontolerant pe-
ripheral MBP-specific T cells in vitro. Investigation is un-
derway to determine which cell types mediate the suppres-
sion and whether this bystander suppression is mediated by
soluble factors and/or is cell contact dependent.
Despite tolerance induction of naive MBP-specific CNS
T cells, spontaneous EAE still occurs in a percentage of the
MBP TCR transgenic mice, primarily within an age win-
dow of 5–12 wk (14). Interestingly, our studies show that
at the age when the incidence of spontaneous EAE in MBP
TCR1 transgenic mice declines, the number of MBP-spe-
cific T cells in the CNS of these mice doubles and their
phenotype converts to that of an activated/memory T cell.
This increase in activated/memory T cells is due in part to
expression of the MBP-specific TCR because the number
of memory T cells is greater in the CNS of older TCR
transgenic mice than in the CNS of age-matched nontrans-
genic mice, and much of this increase in MBP TCR trans-
genic mice can be accounted for by an increase in MBP-
specific (Va21) memory cells. Thus, although T cells in
older MBP TCR transgenic mice appear to have encoun-
tered antigen more frequently than T cells in older non-
transgenic mice, this encounter is not correlated with initi-
ation of disease. Spontaneous EAE may be prevented in
older MBP TCR transgenic mice by the development of
nontransgenic CD41 regulatory T cells that have been
shown to be critical in prevention of spontaneous EAE (12,
47, 48). These regulatory T cells must not function by de-
creasing exposure of MBP-specific T cells to antigen since
memory MBP-specific T cells accumulate in older MBP
TCR transgenic mice, but rather the regulatory T cells
must change the outcome of this interaction.
In summary, our experiments suggest a model in which
naive MBP-specific T cells that escape thymic or peripheral
tolerance traffic at a low frequency through the CNS in
normal individuals. These T cells are prevented from initi-
ating CNS autoimmune disease by in situ tolerance when
they encounter antigen within the CNS. The spontaneous
autoimmune disease that occurs in some mice may be
caused by a failure of tolerance at several levels. Peripheral
events could activate MBP-specific T cells either by immu-
nization, as is the common mechanism for the induction of
EAE, or via molecular mimicry mediated by an infectious
agent (49–53). Once activated, the MBP-specific T cells
are no longer susceptible to tolerance in situ and can initiate
autoimmune disease. Alternatively, autoimmunity could de-
velop because tolerance occurring within the CNS is cir-
cumvented. Potential mechanisms for overcoming toler-
ance in the CNS include an infection that may increase
costimulation and MHC expression in situ, genetic defects
in the tolerance mechanisms, or peripheral infections that
may influence antigen presentation within the CNS
through the release of soluble factors. These experiments
reveal a new form of immunoregulation of CNS-specific T
cells that must be considered in the study of the pathogene-
sis of CNS autoimmunity.
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